000181016 001__ 181016
000181016 005__ 20240303005210.0
000181016 0247_ $$2doi$$a10.1055/a-1853-8291
000181016 0247_ $$2pmid$$apmid:35917826
000181016 0247_ $$2ISSN$$a0015-8151
000181016 0247_ $$2ISSN$$a0340-1618
000181016 0247_ $$2ISSN$$a0367-2239
000181016 0247_ $$2ISSN$$a0936-6652
000181016 0247_ $$2ISSN$$a1433-5972
000181016 0247_ $$2ISSN$$a1438-9010
000181016 0247_ $$2ISSN$$a1438-9029
000181016 0247_ $$2altmetric$$aaltmetric:135918820
000181016 037__ $$aDKFZ-2022-01724
000181016 041__ $$aEnglish
000181016 082__ $$a610
000181016 1001_ $$00000-0001-5595-6948$$aVogel-Claussen, Jens$$b0
000181016 245__ $$aDesign and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography [Design und Rationale der HANSE-Studie: Eine ganzheitliche deutsche Lungenkrebs-Früherkennungs-Studie unter Verwendung von Niedrigdosis-Computertomografie].
000181016 260__ $$aStuttgart [u.a.]$$bThieme$$c2022
000181016 3367_ $$2DRIVER$$aarticle
000181016 3367_ $$2DataCite$$aOutput Types/Journal article
000181016 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1670328744_19363
000181016 3367_ $$2BibTeX$$aARTICLE
000181016 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181016 3367_ $$00$$2EndNote$$aJournal Article
000181016 500__ $$a2022 Dec;194(12):1333-1345
000181016 520__ $$aDespite the high prevalence and mortality of lung cancer and proven effectiveness of low-dose computed tomography (LDCT) to reduce mortality, Germany still lacks a national screening program. The German Institute for Quality and Efficiency in Health Care (IQWiG) and the Federal Office for Radiation Protection (BfS) both published positive scientific evaluations recommending a quality-controlled national screening program. IQWiG underlined the importance of a clear risk definition, integrated smoking cessation programs, and quality assurance, highlighting the necessity of procedural optimization. In the HANSE study, former and current smokers aged 55-79 years are assessed for their lung cancer risk by the NELSON and PLCOM2012 risk scores. 5000 high-risk participants, defined as PLCOM2012 6-year risk ≥ 1.58 % or fulfilling NELSON risk inclusion criteria, will be screened by LDCT at baseline and after 12 months. Lung nodules are analyzed by a modified Lung-RADS 1.1 score of the HANSE study, and values of emphysema and coronary calcium are determined and randomly reported to the participants. 7100 low-risk participants serve as a control. All patients are followed-up for up to 10 years. The sensitivity and specificity of the two risk assessments and LDCT screening, effects of the randomized LDCT reporting, efficiency of lung nodule management, and several other factors are assessed to analyze the success and quality of the holistic screening program. The HANSE study is designed as a holistic lung cancer screening study in northern Germany to answer pressing questions for a successful implementation of an effective German lung cancer screening program. · HANSE is designed to address pressing questions for the implementation of lung cancer screening in Germany.. · HANSE compares NELSON and PLCOM2012 risk assessments for optimal definition of the high-risk group. . · HANSE integrates cardiac calcium and pulmonary emphysema scoring in a holistic screening approach..· Vogel-Claussen J, Lasch F, Bollmann B et al. Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography. Fortschr Röntgenstr 2022; DOI: 10.1055/a-1853-8291.
000181016 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000181016 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181016 7001_ $$aLasch, Florian$$b1
000181016 7001_ $$aBollmann, Benjamin-Alexander$$b2
000181016 7001_ $$aMay, Katharina$$b3
000181016 7001_ $$aKuhlmann, Alexander$$b4
000181016 7001_ $$aSchmid-Bindert, Gerald$$b5
000181016 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b6$$udkfz
000181016 7001_ $$aBarkhausen, Jörg$$b7
000181016 7001_ $$aBohnet, Sabine$$b8
000181016 7001_ $$aReck, Martin$$b9
000181016 773__ $$0PERI:(DE-600)2031079-1$$a10.1055/a-1853-8291$$gp. a-1853-8291$$n12$$p1333-1345$$tRöFo$$v194$$x0015-8151$$y2022
000181016 909CO $$ooai:inrepo02.dkfz.de:181016$$pVDB
000181016 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000181016 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000181016 9141_ $$y2022
000181016 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000181016 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000181016 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-05$$wger
000181016 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-05
000181016 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-05
000181016 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-05
000181016 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-05
000181016 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-05
000181016 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bROFO-FORTSCHR RONTG : 2021$$d2022-11-05
000181016 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-05
000181016 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000181016 980__ $$ajournal
000181016 980__ $$aVDB
000181016 980__ $$aI:(DE-He78)C020-20160331
000181016 980__ $$aUNRESTRICTED